Replies to post #252182 on Biotech Values

[DewDiligence]

AXL? Is that a typo?

[DewDiligence]

Re: PFE’s CD47 program

Clinicaltrials.gov shows these active phase-2 or phase-1/2 trials for PFE’s CD47 agent, Maplirpacept (PF-07901801):

https://www.clinicaltrials.gov/study/NCT05626322
https://www.clinicaltrials.gov/study/NCT05896163

Maplirpacept was also listed in the slide set for PFE’s Feb 2024 Oncology Day (https://investors.pfizer.com/files/doc_downloads/2024/02/29/Pfizer-Oncology-Innovation-Day-Presentation_FINAL.pdf , #18), although there were no further details.